{
    "nctId": "NCT00191269",
    "briefTitle": "Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen",
    "officialTitle": "A Multicenter Study of LY188011 in Anthracyclines and Taxanes Pre-treated Metastatic/Recurrent Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 68,
    "primaryOutcomeMeasure": "Tumor Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically and/or cytologically confirmed breast cancer\n* Received prior chemotherapy for metastatic breast cancer with anthracycline and taxane regimen\n* To have at least one measurable region\n* PS: 0-1\n* To have adequate organ function (bone marrow, liver and renal function)\n\nExclusion Criteria:\n\n* To have Interstitial pneumonia or pulmonary fibrosis\n* To have inflammatory carcinoma\n* Within 28 days after the latest chemotherapy or radiotherapy, 14 days after the latest hormonal/immunotherapy or 7 days after surgery\n* To have brain metastasis with symptom\n* To have severe complication (cardiac infarction, infection, drug hyper sensitivity or diabetes)",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}